Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Chemotherapy resistance remains a significant challenge in breast cancer treatment.
• Methylation-controlled J protein (MCJ) regulates mitochondrial respiration and influences drug sensitivity.
• Identifying markers for chemoresistance is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the role of MCJ expression as a predictive marker for chemotherapy response and survival in breast cancer.
• To elucidate the mechanisms by which MCJ influences chemoresistance in vivo.

Main Methods:

• Retrospective analysis of a large cohort of breast cancer patients treated with chemotherapy.
• Prospective study of patients undergoing neoadjuvant therapy.
• In vivo studies using MCJ-deficient mice models.

Main Results:

• Low MCJ expression in tumors correlated with a high risk of relapse in patients receiving chemotherapy.
• MCJ expression did not correlate with response to endocrine therapy.
• Low MCJ expression predicted poor clinical response to chemotherapy and reduced disease-free survival in a prospective study.
• MCJ deficiency was sufficient to induce mammary tumor chemoresistance in vivo.

Conclusions:

• MCJ is a predictive marker for chemotherapy response in breast cancer.
• Loss of MCJ expression promotes chemoresistance by modulating mitochondrial function.
• Targeting MCJ or its pathway may offer new strategies to overcome chemotherapy resistance in breast cancer.